Grading Liver Dysfunction According to British Columbia Cancer Agency
I was unable to locate specific grading criteria from the British Columbia Cancer Agency in the provided evidence. The evidence primarily discusses CTCAE (Common Terminology Criteria for Adverse Events) grading systems used in oncology trials, but does not reference a distinct British Columbia Cancer Agency liver dysfunction grading system.
Standard Oncology Grading Systems Referenced in the Evidence
The most widely used grading system in cancer centers, including those in British Columbia, is the CTCAE version 5.0, which grades liver enzyme elevations based on whether baseline values are normal or abnormal 1.
For Patients with Normal Baseline Liver Tests
The CTCAE grading for ALT and AST elevations is structured as follows 1:
- Grade 1 (Mild): >ULN to 3× ULN
- Grade 2 (Moderate): >3 to 5× ULN
- Grade 3 (Severe): >5 to 20× ULN
- Grade 4 (Life-threatening): >20× ULN
For Patients with Abnormal Baseline Liver Tests
When baseline liver tests are already elevated, grading uses multiples of baseline (BSL) rather than ULN 1:
- Grade 1: 1.5 to 3× baseline
- Grade 2: >3 to 5× baseline
- Grade 3: >5 to 20× baseline
- Grade 4: >20× baseline
Important Caveats and Limitations
The CTCAE grading system has significant limitations and is not recommended for assessment and management of hepatotoxicity without further modification 1. Key issues include:
- Grade 3 represents an excessively broad range (5-20× ULN), which becomes even more problematic in patients with abnormal baselines 1
- Patients with abnormal baselines may be categorized as having mild or moderate injury when ALT levels are actually consistent with severe injury 1
- The magnitude of ALT elevation correlates poorly with actual severity of liver injury—clinical indicators like INR, serum albumin, and bilirubin are more important 1
Hepatitis Grading in Immunotherapy Context
For immune checkpoint inhibitor-related hepatitis, ASCO guidelines provide more clinically relevant grading 1:
- Grade 1: AST or ALT >ULN to 3.0× ULN and/or total bilirubin >ULN to 1.5× ULN (asymptomatic)
- Grade 2: AST or ALT >3.0 to ≤5.0× ULN and/or total bilirubin >1.5 to ≤3.0× ULN (asymptomatic)
- Grade 3: AST or ALT 5-20× ULN and/or total bilirubin 3-10× ULN, OR symptomatic liver dysfunction
- Grade 4: AST or ALT >20× ULN and/or total bilirubin >10× ULN OR decompensated liver function (ascites, coagulopathy, encephalopathy, coma)
Practical Management Thresholds
Well-established action thresholds for oncology patients with normal baseline ALT include 3,5,8 (or 10), and 20× ULN, triggering escalating actions from increased monitoring to permanent treatment discontinuation 1. Elevations of total or direct bilirubin associated with ALT/AST ≥3× ULN indicate more severe hepatocellular injury and generally require drug hold or permanent discontinuation 1.